Review of cannabinoid potential for treating neurological diseases
Cannabinoids showed therapeutic potential for multiple neurological conditions in experimental and clinical studies, though psychotropic side effects remained the main barrier to wider clinical use.
Quick Facts
What This Study Found
This review evaluated the state of cannabinoid research for neurological diseases. Established clinical uses at the time included glaucoma treatment, chemotherapy-related nausea and vomiting, appetite stimulation in HIV-related wasting, and MS symptom management.
Research efforts were increasingly focused on targeting cannabinoid receptor activity in the central nervous system for neurodegenerative diseases (Alzheimer's, Parkinson's, Huntington's, ALS), as well as psychiatric and non-psychiatric neurological conditions. The review emphasized that overcoming psychotropic side effects remained the central challenge for expanding clinical use of cannabinoids.
CBD, which lacks psychotropic effects, was highlighted as having particular promise due to its neuroprotective and anti-inflammatory properties without the psychoactive limitations of THC.
Key Numbers
Four established clinical indications were reviewed: glaucoma, chemotherapy nausea, HIV-related wasting, and MS spasticity. Multiple neurodegenerative conditions were under experimental investigation.
How They Did This
Review of published experimental and clinical studies on cannabinoid use in neurological diseases, including both preclinical animal models and available human data.
Why This Research Matters
This review captured a moment when cannabinoid neurology was transitioning from established uses (nausea, appetite, spasticity) toward potential applications in neurodegenerative diseases, reflecting growing understanding of the endocannabinoid system's role in brain health.
The Bigger Picture
The traditional reputation of cannabis as a recreational drug obscures centuries of medicinal use. This review traced the progression from ancient therapeutic applications through modern efforts to isolate specific cannabinoid actions for targeted neurological treatments.
What This Study Doesn't Tell Us
Much of the neurodegeneration evidence was preclinical. Clinical trials for most neurological conditions were small or absent. The challenge of separating therapeutic from psychotropic effects had not been fully solved for THC-based approaches.
Questions This Raises
- ?Have any cannabinoid treatments for neurodegenerative diseases reached clinical trials since 2014?
- ?Can peripherally restricted cannabinoids provide neuroprotection without psychotropic effects?
- ?Is CBD's neuroprotective potential being realized in clinical practice?
Trust & Context
- Key Stat:
- Four established clinical uses with emerging evidence for neurodegenerative diseases
- Evidence Grade:
- Broad review mixing established clinical evidence with preclinical findings for emerging applications.
- Study Age:
- Published in 2014. CBD has since been approved for epilepsy, and research in neurodegeneration continues.
- Original Title:
- Cannabinoids: new promising agents in the treatment of neurological diseases.
- Published In:
- Molecules (Basel, Switzerland), 19(11), 18781-816 (2014)
- Authors:
- Giacoppo, Sabrina(2), Mandolino, Giuseppe(3), Galuppo, Maria(2), Bramanti, Placido, Mazzon, Emanuela
- Database ID:
- RTHC-00798
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What neurological conditions might cannabinoids help with?
Established uses included MS spasticity, chemotherapy nausea, glaucoma, and appetite stimulation. Experimental evidence existed for Alzheimer's, Parkinson's, Huntington's, and ALS, though clinical trials were lacking for most neurodegenerative applications.
Why aren't cannabinoids more widely used in neurology?
The main barrier was psychotropic side effects from THC. CBD, which lacks these effects, was highlighted as having particular promise for neurological applications due to its neuroprotective and anti-inflammatory properties.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-00798APA
Giacoppo, Sabrina; Mandolino, Giuseppe; Galuppo, Maria; Bramanti, Placido; Mazzon, Emanuela. (2014). Cannabinoids: new promising agents in the treatment of neurological diseases.. Molecules (Basel, Switzerland), 19(11), 18781-816. https://doi.org/10.3390/molecules191118781
MLA
Giacoppo, Sabrina, et al. "Cannabinoids: new promising agents in the treatment of neurological diseases.." Molecules (Basel, 2014. https://doi.org/10.3390/molecules191118781
RethinkTHC
RethinkTHC Research Database. "Cannabinoids: new promising agents in the treatment of neuro..." RTHC-00798. Retrieved from https://rethinkthc.com/research/giacoppo-2014-cannabinoids-new-promising-agents
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.